Malmberg L Pekka, Pelkonen Anna S, Vartiainen Ville, Vahteristo Mikko, Lähelmä Satu, Jõgi Rain
Unit of Clinical Physiology, Skin and Allergy Hospital, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
Research and Development, Orion Corporation, Espoo, Finland.
J Thorac Dis. 2021 Feb;13(2):621-631. doi: 10.21037/jtd-20-2112.
To evaluate whether patients of varying ages and lung function with asthma or those with chronic obstructive pulmonary disease (COPD) can achieve sufficient inspiratory flows for effective use of the fixed-dose combination of salmeterol-fluticasone propionate and budesonide-formoterol dispensed with the Easyhaler (EH) device-metered, multi-dose dry powder inhaler (DPI).
A pooled analysis of two randomized, multicenter, crossover, open-label studies (NCT01424137; NCT009849061) was conducted to characterize inspiratory flow parameters across the EH, Seretide Diskus (DI) and Symbicort Turbuhaler (TH) inhalers in patients with asthma and/or COPD of varying severity. The primary endpoint was peak inspiratory flow (PIF) rate through the EH.
The intent-to-treat population comprised 397 patients; 383 patients were included in the per-protocol (PP) population. The mean PIF (standard deviation) values through the EH in patients <18 and ≥18 years of age with asthma and in those with COPD, were similar: 61.4 (11.5), 69.7 (13.5), and 61.9 (13.2) L/min, respectively. These flow rates correspond to pressure drops of 5.05 (1.80), 6.52 (2.34) and 5.19 (2.07) kPa, respectively. In total, 380 (99.2%) of patients in the PP population were able to generate a PIF rate through the EH of ≥30 L/min, which is required to enable consistent dose delivery from the DPI; there was a moderate direct association between age and PIF in younger patients with asthma, but this was inverse and less apparent in adult patients with asthma and/or those with COPD. Height and weight were also moderately correlated with PIF. Stronger associations with PIF were observed for some lung function parameters, particularly native PIF and forced inspiratory vital capacity.
Over 99% of patients with asthma and/or COPD were able to inhale through the EH with an adequate PIF rate, irrespective of age, or severity of airway obstruction. This confirms that patients with asthma and/or COPD can achieve inspiratory flows via the EH DPI that are sufficient for its effective use.
评估不同年龄和肺功能的哮喘患者或慢性阻塞性肺疾病(COPD)患者使用易纳器(EH)装置(一种定量、多剂量干粉吸入器)所提供的沙美特罗-丙酸氟替卡松和布地奈德-福莫特罗固定剂量组合时,能否获得足够的吸气流速以实现有效使用。
对两项随机、多中心、交叉、开放标签研究(NCT01424137;NCT009849061)进行汇总分析,以描述不同严重程度的哮喘和/或COPD患者使用EH、舒利迭准纳器(DI)和信必可都保(TH)吸入器时的吸气流速参数。主要终点是通过EH的最大吸气流速(PIF)。
意向性治疗人群包括397例患者;符合方案(PP)人群包括383例患者。年龄<18岁和≥18岁的哮喘患者以及COPD患者通过EH的平均PIF(标准差)值相似,分别为61.4(11.5)、69.7(13.5)和61.9(13.2)L/分钟。这些流速分别对应于5.05(1.80)、6.52(2.34)和5.19(2.07)kPa的压力降。PP人群中共有380例(99.2%)患者能够通过EH产生≥30L/分钟的PIF,这是使干粉吸入器能够持续给药所需的;在较年轻的哮喘患者中,年龄与PIF之间存在中度正相关,但在成年哮喘患者和/或COPD患者中,这种相关性呈负相关且不太明显。身高和体重也与PIF中度相关。对于一些肺功能参数,尤其是固有PIF和用力吸气肺活量,观察到与PIF有更强的相关性。
超过99%的哮喘和/或COPD患者能够以足够的PIF通过EH进行吸入,无论年龄或气道阻塞的严重程度如何。这证实了哮喘和/或COPD患者可以通过EH干粉吸入器获得足以有效使用的吸气流速。